Email this article PROSPECTS OF THE USE OF PHOSPHAZIDE IN THE SCHEDULES OF ANTIRETROVIRAL THERAPY FOR HIV INFECTION
- Authors: Vorobiova N.N.1, Ivanova E.S.2
-
Affiliations:
- Perm State Medical Academy named after Acad. E.A. Vagner
- Perm Regional Centre of Prevention and Control of AIDS and infectious diseases
- Issue: Vol 18, No 4 (2013)
- Pages: 58-61
- Section: Articles
- URL: https://journals.rcsi.science/1560-9529/article/view/40772
- DOI: https://doi.org/10.17816/EID40772
- ID: 40772
Cite item
Full Text
Abstract
The aim of the study was to evaluate the effectiveness of triple antiretroviral theтру, including domestic product Phosphazide in 18 HIV-infected patients during 48 weeks. There was determined the dynamics of the clinical manifestations of the disease, the parameters of viral load and CD4 lymphocytes before antiretroviral therapy (ART), and 4, 12, 24, 36 and 48 weeks after its use. The study showed high virological and sufficient immunologic efficacy of this schedule.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
N. N. Vorobiova
Perm State Medical Academy named after Acad. E.A. Vagner
Email: infect-perm@mail.ru
доктор мед. наук, проф., зав. каф. инфекционных болезней
E. S. Ivanova
Perm Regional Centre of Prevention and Control of AIDS and infectious diseasesзав отделом лечебной помощи
References
- Bartlett J.A., Ribaudo H.J., Wallis C.L. et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012; 26 (11): 1345— 54. doi: 10.1097/QAD.0b013e328353b066.
- Покровский В.В., Юрин О.Г., Кравченко А.В. и др. "Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией". Эпидемиология и инфекционные болезни. 2012; 6 (прил.): 1-48.
- Pulido F., Arribas J.R., Delgado R. et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008; 22 (2): F1-9.
- Brinkman K., Hofstede H., Burger D.M., Smeitink J.A., Koop-mans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12: 1735-44.
- Weerawat Manosuth, Supeda Thongyen, Samruay Nilkamhang. Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure. AIDS Res Ther. 2012; 9: 8. Published online 2012 March 13. doi: 10.1186/1742-6405-9-8. PMCID: PMC3317876.
- Kravchenko A.V., Kanestri V.G., Gankina N.Ju. Application Phosphazide in the antiretroviral therapy. Infect. Dis. 2011; 9 (4): 64-9.
- Geretti A.M., Arribas J.R., Lathouwers E. et al. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. HIV Clin Trials. 2013; 14 (1): 45-50. doi: 10.1410/hct1401-45.
- Brehm J.H., Scott Y., KoontzD.L. et al. Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase. PLoS One. 2012; 7 (2): e31558. Published online 2012 February 21. doi: 10.1371/jour-nal.pone.0031558. PMCID: PMC3283647.
- Lander B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989; 246: 1155-8.
- Сизова Н.В., Губа З.В., Торопов С.Ю., Захарова Н.Г., Рахманова А.Г. Фосфазид - отечественный препарат для лечения ВИЧ-инфекции. Второе рождение. ВИЧ-инфекция и иммуносупрессии. 2012; 4 (2): 45-53.
- Пантелеев A.M., Голиусова М.Ю., Кабанова В.И. Результаты применения фосфазида (никавира) у пациентов с сочетанной ВИЧ-инфекцией и туберкулезом. ВИЧ-инфекция и иммуносупрессия. 2010; 2 (2): 75-9.
- Иванова Э., Шмагель Н., Воробьева Н. Никавир в режимах химиопрофилакики вертикального пути передачи. Понимание ВИЧ/СПИД по ведению и лечению. В кн.: Файсон Ханания Касенга, ред. Пандемия в 21 веке. Хорватия; 2011: 125-48.
- Иванова Э. Эффективность фосфазида в антиретровирусной терапии. В кн.: Материалы XVIII Международной конференции по СПИДу. Вена; 2010. Abstr. THPE0110.
Supplementary files
